MOWOOT, a pioneering growth-stage medical device company specializing in the treatment of intestinal transit disorders, has successfully raised $2,000,000 in funding to advance its innovative non-drug, non-invasive solution. Founded in 2014 and emerging from the esteemed Stanford Biodesign-inspired dHEALTH BCN program, MOWOOT's revolutionary device leverages a unique mechanism called Intermittent Colonic Exoperistalsis (ICE), developed in collaboration with the renowned Institut Guttmann in Barcelona. This clinically proven technology offers relief for a range of conditions, including neurogenic bowel disorder, chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation. The company aims to utilize the newly acquired funds to enhance product development, expand clinical research, and establish strategic partnerships across European markets, where it has already been recognized in various clinical guidelines and textbooks. MOWOOT's visionary founder team—which includes a diverse group of experts, such as CEO Markus Wilhelms, PhD in Molecular Microbiology; CSO/COO Immaculada Herrero Fresneda, PhD in Biological Sciences; CCO Marc Benet Pozo; and CTO Àngel Calzada Defez, PhD in Telecommunications—brings a wealth of knowledge and passion to the mission of transforming the treatment landscape for patients with debilitating intestinal disorders. With this new support, MOWOOT is poised to make significant strides in improving patient quality of life without the side effects associated with traditional therapies.








